

Nanna Witting

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2712686/publications.pdf>

Version: 2024-02-01

58
papers

2,056
citations

279487

23
h-index

243296

44
g-index

58
all docs

58
docs citations

58
times ranked

2654
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. <i>Lancet Neurology</i> , 2017, 16, 976-986.	4.9	472
2	Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. <i>Muscle and Nerve</i> , 2019, 60, 14-24.	1.0	162
3	Cardiac manifestations of myotonic dystrophy type 1. <i>International Journal of Cardiology</i> , 2012, 160, 82-88.	0.8	146
4	A PET activation study of brush-evoked allodynia in patients with nerve injury pain. <i>Pain</i> , 2006, 120, 145-154.	2.0	122
5	Congenital Titinopathy: Comprehensive characterization and pathogenic insights. <i>Annals of Neurology</i> , 2018, 83, 1105-1124.	2.8	93
6	A heterozygous 21-bp deletion in <i>CAPN3</i> causes dominantly inherited limb girdle muscular dystrophy. <i>Brain</i> , 2016, 139, 2154-2163.	3.7	87
7	Anoctamin 5 muscular dystrophy in Denmark: prevalence, genotypes, phenotypes, cardiac findings, and muscle protein expression. <i>Journal of Neurology</i> , 2013, 260, 2084-2093.	1.8	63
8	Two- and 6-minute walk tests assess walking capability equally in neuromuscular diseases. <i>Neurology</i> , 2016, 86, 442-445.	1.5	51
9	Clinical and genetic spectrum in limb-girdle muscular dystrophy type 2E. <i>Neurology</i> , 2015, 84, 1772-1781.	1.5	50
10	The antimyotonic effect of lamotrigine in non-dystrophic myotonias: a double-blind randomized study. <i>Brain</i> , 2017, 140, 2295-2305.	3.7	49
11	High prevalence of cardiac involvement in patients with myotonic dystrophy type 1: A cross-sectional study. <i>International Journal of Cardiology</i> , 2014, 174, 31-36.	0.8	44
12	Axial myopathy: an overlooked feature of muscle diseases. <i>Brain</i> , 2016, 139, 13-22.	3.7	44
13	Myocardial fibrosis in patients with myotonic dystrophy type 1: a cardiovascular magnetic resonance study. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2014, 16, 59.	1.6	43
14	Effect of sildenafil on skeletal and cardiac muscle in Becker muscular dystrophy. <i>Annals of Neurology</i> , 2014, 76, 550-557.	2.8	39
15	Progression of cardiac involvement in patients with limb-girdle type 2 and Becker muscular dystrophies: A 9-year follow-up study. <i>International Journal of Cardiology</i> , 2015, 182, 403-411.	0.8	36
16	Phenotypes, genotypes, and prevalence of congenital myopathies older than 5 years in Denmark. <i>Neurology: Genetics</i> , 2017, 3, e140.	0.9	34
17	Panel-Based Exome Sequencing for Neuromuscular Disorders as a Diagnostic Service. <i>Journal of Neuromuscular Diseases</i> , 2019, 6, 241-258.	1.1	32
18	Eculizumab improves fatigue in refractory generalized myasthenia gravis. <i>Quality of Life Research</i> , 2019, 28, 2247-2254.	1.5	32

#	ARTICLE	IF	CITATIONS
19	Phenotype and genotype of muscle ryanodine receptor rhabdomyolysis-myalgia syndrome. <i>Acta Neurologica Scandinavica</i> , 2018, 137, 452-461.	1.0	31
20	MSTO1 mutations cause mtDNA depletion, manifesting as muscular dystrophy with cerebellar involvement. <i>Acta Neuropathologica</i> , 2019, 138, 1013-1031.	3.9	31
21	Recurrent <i>TTN</i> metatranscript ^{only} c.39974 ^{11T>} G splice variant associated with autosomal recessive arthrogyposis multiplex congenita and myopathy. <i>Human Mutation</i> , 2020, 41, 403-411.	1.1	28
22	Pharmacologic Treatment of Downstream of Tyrosine Kinase 7 Congenital Myasthenic Syndrome. <i>JAMA Neurology</i> , 2014, 71, 350.	4.5	27
23	Role of neuronal nitric oxide synthase (nNOS) in Duchenne and Becker muscular dystrophies – Still a possible treatment modality?. <i>Neuromuscular Disorders</i> , 2018, 28, 914-926.	0.3	24
24	Decreased Variability of the 6-Minute Walk Test by Heart Rate Correction in Patients with Neuromuscular Disease. <i>PLoS ONE</i> , 2014, 9, e114273.	1.1	24
25	Ocular, bulbar, limb, and cardiopulmonary involvement in oculopharyngeal muscular dystrophy. <i>Acta Neurologica Scandinavica</i> , 2014, 130, 125-130.	1.0	23
26	Severe Axial Myopathy in McArdle Disease. <i>JAMA Neurology</i> , 2014, 71, 88.	4.5	18
27	Prevalence and phenotypes of congenital myopathy due to β -actin 1 gene mutations. <i>Muscle and Nerve</i> , 2016, 53, 388-393.	1.0	18
28	Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study. <i>Journal of the Neurological Sciences</i> , 2019, 407, 116419.	0.3	18
29	Frequency and phenotype of patients carrying TPM2 and TPM3 gene mutations in a cohort of 94 patients with congenital myopathy. <i>Neuromuscular Disorders</i> , 2014, 24, 325-330.	0.3	17
30	Aerobic Training in Patients with Congenital Myopathy. <i>PLoS ONE</i> , 2016, 11, e0146036.	1.1	17
31	Permanent muscle weakness in hypokalemic periodic paralysis. <i>Neurology</i> , 2020, 95, e342-e352.	1.5	17
32	Consistent improvement with eculizumab across muscle groups in myasthenia gravis. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1327-1339.	1.7	16
33	Becker muscular dystrophy with widespread muscle hypertrophy and a non-sense mutation of exon 2. <i>Neuromuscular Disorders</i> , 2013, 23, 25-28.	0.3	15
34	Effects of Sildenafil on Cerebrovascular Reactivity in Patients with Becker Muscular Dystrophy. <i>Neurotherapeutics</i> , 2017, 14, 182-190.	2.1	14
35	Muscle involvement assessed by quantitative magnetic resonance imaging in patients with anoctamin 5 deficiency. <i>European Journal of Neurology</i> , 2021, 28, 3121-3132.	1.7	13
36	Collagen XII myopathy with rectus femoris atrophy and collagen XII retention in fibroblasts. <i>Muscle and Nerve</i> , 2018, 57, 1026-1030.	1.0	11

#	ARTICLE	IF	CITATIONS
37	Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of <sc>REGAIN</sc> and its extension study. <i>Muscle and Nerve</i> , 2021, 64, 662-669.	1.0	11
38	Frequency and Phenotype of Myotubular Myopathy Amongst Danish Patients with Congenital Myopathy Older than 5 Years. <i>Journal of Neuromuscular Diseases</i> , 2015, 2, 167-174.	1.1	10
39	Congenital myopathies are mainly associated with a mild cardiac phenotype. <i>Journal of Neurology</i> , 2019, 266, 1367-1375.	1.8	10
40	Quantitative Muscle MRI as Outcome Measure in Patients With Becker Muscular Dystrophyâ€”A 1-Year Follow-Up Study. <i>Frontiers in Neurology</i> , 2020, 11, 613489.	1.1	9
41	Intrarater reliability and validity of outcome measures in myotonic dystrophy type 1. <i>Neurology</i> , 2020, 94, e2508-e2520.	1.5	7
42	Physical activity in myotonic dystrophy type 1. <i>Journal of Neurology</i> , 2020, 267, 1679-1686.	1.8	7
43	Cardiac arrest in anti-mitochondrial antibody associated inflammatory myopathy. <i>Oxford Medical Case Reports</i> , 2021, 2021, omaa150.	0.2	6
44	Muscle biopsy and <sc>MRI</sc> findings in <sc>ANO5</sc>-related myopathy. <i>Muscle and Nerve</i> , 2021, 64, 743-748.	1.0	6
45	Botulinum toxin treatment improves dysphagia in patients with oculopharyngeal muscular dystrophy and sporadic inclusion body myositis. <i>Journal of Neurology</i> , 2022, 269, 4154-4160.	1.8	6
46	Clinical and neurophysiological response to pharmacological treatment of DOK7 congenital myasthenia in an older patient. <i>Clinical Neurology and Neurosurgery</i> , 2015, 130, 168-170.	0.6	5
47	Deletion of exon 26 of the dystrophin gene is associated with a mild Becker muscular dystrophy phenotype. <i>Acta Myologica</i> , 2011, 30, 182-4.	1.5	5
48	Axial muscle involvement in patients with limb girdle muscular dystrophy type <sc>R9</sc>. <i>Muscle and Nerve</i> , 2022, 65, 405-414.	1.0	3
49	Responsiveness of outcome measures in myotonic dystrophy type 1. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1382-1391.	1.7	2
50	Contractile properties are impaired in congenital myopathies. <i>Neuromuscular Disorders</i> , 2020, 30, 649-655.	0.3	2
51	Patients With Becker Muscular Dystrophy Have Severe Paraspinal Muscle Involvement. <i>Frontiers in Neurology</i> , 2021, 12, 613483.	1.1	2
52	Autophagy is affected in patients with hypokalemic periodic paralysis: an involvement in vacuolar myopathy?. <i>Acta Neuropathologica Communications</i> , 2021, 9, 109.	2.4	2
53	Altered somatosensory neurovascular response in patients with Becker muscular dystrophy. <i>Brain and Behavior</i> , 2018, 8, e00985.	1.0	1
54	Progression or Not â€” A Small Natural History Study of Genetical Confirmed Congenital Myopathies. <i>Journal of Neuromuscular Diseases</i> , 2021, 8, 647-655.	1.1	1

#	ARTICLE	IF	CITATIONS
55	Response. <i>Neuromuscular Disorders</i> , 2013, 23, 193.	0.3	0
56	AB0652â€¦QTC INTERVAL PROLONGATION IN A SCANDINAVIAN COHORT OF PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES AND SYSTEMIC SCLEROSIS: CORRELATIONS WITH CLINICAL VARIABLES. , 2019, , .		0
57	FRI0320â€¦CN-1A AUTOANTIBODIES ARE SPECIFIC FOR SPORADIC INCLUSION BODY MYOSITIS. , 2019, , .		0
58	Effects of rhythmic auditory stimulation on walking during the 6-minute walk test in patients with generalised Myasthenia Gravis. <i>European Journal of Physiotherapy</i> , 0, , 1-000.	0.7	0